Continuous extrapleural infusion of ropivacaine 0.2% after cardiovascular surgery via the lateral thoracotomy approach Abstract OBJECTIVE: The pharmacokinetics of ropivacaine 0.2% were evaluated during a 48-hour continuous extrapleural infusion with 2 different infusion rates in patients undergoing cardiovascular surgery. The hypotheses that no toxic plasma concentrations of ropivacaine would be reached and that proportionality exists among plasma concentrations and dosage used were tested. DESIGN: A prospective, randomized, nonblinded study. SETTING: The investigation was performed as a single-center study in the Division of Cardiovascular Anesthesia, University Hospital of Zurich, in Switzerland. PARTICIPANTS: Seventeen consenting adults scheduled for elective cardiovascular surgery, with or without extracorporeal bypass, via the lateral thoracotomy approach were enrolled. INTERVENTIONS: For postoperative pain relief, patients were randomly assigned to receive continuous extrapleural infusion of ropivacaine 0.2% at a rate of either 6 or 9 mL/h over 48 hours. MEASUREMENTS AND MAIN RESULTS: Plasma concentrations of ropivacaine reached toxic levels (>2.2 mg/L) in 25% of cases. No proportionality of plasma concentrations of ropivacaine existed when the 2 dosing regimens were compared. CONCLUSIONS: Plasma concentrations of ropivacaine, administered at the given dose and rates during continuous extrapleural infusion, are unpredictable and may reach toxic levels in patients undergoing major cardiothoracic surgery. 
Introduction
For patients selected for cardiovascular surgery, the left thoracotomy approach is a suitable alternative to the standard median sternotomy (1) . However, pain after thoracic surgery has long been recognized as a cause of postoperative pulmonary morbidity (2) , and is associated with inadequate ventilation, insufficient coughing, atelectasis, mucous plugging, hypoxia, and pulmonary infection (3, 4) . Parenteral opioids relieve acute postoperative pain in many patients at rest, but are associated with side effects such as respiratory depression, nausea, and bowel dysfunction.
The health of patients undergoing cardiovascular surgery is often compromised by cardiac performance and pulmonal function. This limits the postoperative administration of opioids. Epidural analgesia has been widely advocated as a means of controlling postthoracotomy pain (5, 6) , but its use is controversial when extracorporeal circulation is used (7) .
The use of an extrapleural catheter, originally described by Sabanathan and associates (8) , is a valid alternative to continuous epidural analgesia for relieving postthoracotomy pain (2, 9, 10) . In contrast to bupivacaine, only one study provides information about the pharmacokinetics and efficacy of ropivacaine during long-term continuous extrapleural infusion (11) . It is thought to possess a greater margin of safety than bupivacaine, however (12, 13) .
The aim of this study was to evaluate the pharmacokinetics of a 48-hour continuous extrapleural ropivacaine infusion following cardiovascular surgery with lateral thoracotomy. We assessed the pharmacokinetics of ropivacaine 0.2%, applied at a rate of 6 or 9ml/h. The primary endpoints were the plasma concentrations of total and unbound ropivacaine, and [alpha] 1 -acid glycoprotein.
Our hypotheses were that no toxic plasma concentrations of ropivacaine would be reached (12) and that proportionality exists between plasma concentrations and dosage used.
Materials and Methods

Patients
We performed a power analysis using previously published data (14) to determine the sample size where blood concentrations of total and unbound ropivacaine at the chosen infusion rates are expected to be different:. A two sided t-test with an error level of 0.05 and a power of 80% resulted in a sample size of total 16 patients. After obtaining institutional ethics committee approval (University Hospital of Zurich, Switzerland) and written informed consent, adult patients were prospectively enrolled when scheduled for elective cardiovascular surgery -with or without extracorporeal circulation -in which lateral thoracothomy was the chosen surgical approach. Exclusion criteria were any contraindications to extrapleural analgesia (such as pleural disease); known allergy to ropivacaine, propacetamol, and nicomorphine; administration of local anesthetics within 7 days prior to the present study; pregnancy and women without adequate contraception; concomitant medication with potent cytochrome P-450 1A2 inhibitors (such as fluvoxamine and ciprofloxacin); gamma-GT >100IU/l; creatinine >2.4mg/dl; neurologic disease and neuropsychiatric disorders.
Surgical procedures
Using computer-generated randomization, patients were allocated to receive a continuous extrapleural infusion of ropivacaine 0.2% postoperatively, at a rate of either 6 or 9 ml/h (12 or 18 mg/h). These infusion rates were chosen in order to compare the results directly with the study of Ekatodramis et al. (14) .
Intraoperative analgesia was performed with fentanyl (Fentanyl-Janssen® Janssen-Cilag AG, Switzerland), max. 0.01mg/kg, given within the first two hours of surgery and then completed with remifentanil (Ultiva® GlaxoSmithKline AG, Switzerland) continuous infusion according to the patients needs. One-lung ventilation was introduced before thoracotomy was performed at the level of the 
Data analysis and statistics
The highest drug concentration after the start of the extrapleural infusion (C max ), the time to reach C max (t max ), and the plasma concentration at the end of the infusion (C end ) were derived directly from the data for total and unbound ropivacaine. The unbound fraction (fu) of ropivacaine was calculated as unbound concentration (C u ) divided by total concentration in the same sample.
Following the end of infusion, the terminal half-life (t 1/2 ) was determined for total ropivacaine by linear regression of the four last data points on the plasma All results are presented as mean ± SD or median/upper quartile/lower quartile.
A P value <0.05 was considered to be statistically significant.
Results
Patients and surgical procedures
A total of 17 patients were enrolled in the study: 9 patients were randomized to receive ropivacaine 6ml/h and 8 patients to receive 9ml/h. One patient in the 9ml/h group was excluded from the study because the extrapleural catheter was removed during reexploration of the thorax. Data from 9 patients in the 6ml/h group and 7 patients in the 9ml/h group were analyzed. 11 patients received a thoracic aorta graft or a mitral valve repair, 1 patient underwent aortic isthmus stenosis graft repair, 1 closure of atrial septal defect and 3 patients had surgery for other problems.
Demographic data were statistically similar in both groups, as summarized in Table 1 . Also, the surgery time, time between end of surgery and injection of the first bolus of ropivacaine (t 0 ), the amount of blood products needed during the study period, and the time of extracorporeal circulation did not differ between the two study groups (Table 2 ). However, there was an unexplained trend towards longer surgery time, longer time of extracorporeal circulation and higher need for fluid and blood product replacement in the higher dosage group.
Pharmacokinetic data
Plasma concentrations of total and unbound ropivacaine and of [alpha] 1 -acid glycoprotein increased constantly during the continuous infusion in both groups, without reaching a clear steady state (Figure 1 ). Table 3 shows measured and calculated pharmacokinetic data in the two groups. The only significant differences observed between the two groups were in the unbound fractions (fu 30min and fu end , P <0.001). The unbound fractions decreased significantly over time within each group (fu 30min and fu end , P <0.05).
The total plasma clearance (CL tot ) and the calculated unbound ropivacaine clearance (CL u ) were independent of the infusion dose, but decreased significantly between 6 hours and the end of treatment: Cl tot in the 6ml/h group decreased by 33% (range -6 to -46%); Cl tot in the 9ml/h group decreased by 48% (range -15 to -74%); Cl u in the 6ml/h group decreased by 52% (range -20
to -110%); Cl u in the 9ml/h group decreased by 70% (range -13 to -190%) (P
<0.05 for all values).
In order to measure the average total and unbound ropivacaine concentrations during the infusion period, the area under the curve (AUC) was calculated. The terminal half-life after the end of the infusion was 4.9 ± 3.2h in the 6ml/h group and 6.9 ± 4.8 h in the 9ml/h group (P>0.05) ( Table 3 
Discussion
The main conclusion of this study is that, during continuous extrapleural infusion of ropivacaine 0.2% for postthoracotomy pain, plasma concentrations of total and unbound ropivacaine are unpredictable. In addition, toxic ropivacaine levels were reached in 25 % of patients in the study population (1 case in the low dosage group and 3 cases in the high dosage group).
Several aspects of our results were not in accordance with previous investigations. In contrast with previous studies, we did not observe significant dose-proportional increases in plasma concentrations of total or unbound ropivacaine following infusion (14, 16, 17) . Furthermore, we did not observe any correlations between maximum concentrations of total or unbound ropivacaine and factors (such as body weight, height, blood loss, substituted blood products, fluid balance, liver function parameters, use of extracorporeal circulation or dose per bodyweight) that may influence ropivacaine concentrations.
In four patients, total ropivacaine concentrations exceeded 2.2mg/L, a level previously determined toxic in healthy subjects after intravenous infusion of ropivacaine (12) . Three of those patients were in the high dosage group, suggesting that 9ml/h of ropivacaine 0.2% is too a high dosage for extrapleural analgesia. In contrast to a continuous interscalene infusion (14) , the dynamics of drug dispersal into tissues varies more because distribution can be into vessel rich zones within the intercostal space or into the slowly absorbent tissue over the vertebral bodies (18) . However, with a steady infusion rate, the differences in the kinetics of absorption should not influence the variability of plasma concentrations of the local anasthetic.
In accordance with previous studies, concentrations of unbound ropivacaineprimarily responsible for systemic toxic effects -did not exceed 0.08 in the low infusion group and 0.2 in the high infusion group. Threshold levels for central hours and the end of the infusion suggests that a steady state was not reached after 48 hours. Although only an estimate of the actual value, these observations strongly contrast with previous studies that reported stable unbound concentrations during continuous infusion (11, 14, 20) . A possible explanation is variability in the intrinsic metabolic clearance of ropivacaine (CL int ), assuming that the hepatic extraction ratio of ropivacaine is low and the intrinsic clearance corresponds to the unbound clearance (CL u ). This is supported by our results, in which the plasma clearance of ropivacaine also showed a marked and consistent decrease in the unbound fraction. We assume that steady state would have been reached later and therefore, a longer study period (>48 hours) would provide more information, although at an increased risk of toxicity.
It is unlikely that a single factor alone led to the unpredictable plasma ropivacaine concentrations observed in the current study. We propose, rather, that a combination of factors such as patient co-morbidities (average ASA score 3.4), and surgeries associated with mayor fluid shifts were reflected in our findings.
Previous studies agree on the safety of higher doses of a continuous infusion of ropivacaine. However, our results point out a possible, important caveat, that concentrations of total and unbound ropivacaine may be extremely variable in patients with a high ASA class undergoing cardiovascular surgery. As we have previously suggested, a sound evaluation of the indications and concentrations used for such procedures is urgently needed (21) .
The first priority is, of course, the efficacy of the method. This technique has been shown to be as effective as epidural analgesia for postoperative thoracotomy pain relief (10, 15, 22, 23) . Our results indicate a greater need for pain medication in the 6ml/h group than in the 9ml/h group, although we cannot draw conclusions from this observation because the study was not designed to measure the efficacy of pain relief. For this purpose, the study would require a greater sample size to overcome the intersubject variability seen in our trial, and include a control group.
In summary, our study showed that in patients undergoing major cardiothoracic surgery, plasma concentrations of total and unbound ropivacaine are unpredictable during continuous extrapleural infusion. Furthermore, we identified a high risk of reaching toxic concentrations of ropivacaine using this methodology. We therefore advise a cautious use of continuous extrapleural infusion of ropivacaine in this population. 
